

#stage4needsmore

Phase 3 OnPrime/GOG-3076

IN PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER



clinicaltrials.gov: NCT05281471



Key Reasons to Consider This Study for Your Patients:

- No cap on number of prior lines.
- High-grade serous, endometrioid, or clear-cell ovarian cancer included.
- Primary & secondary platinum-refractory diseases allowed.
- No limitation on BRCA, HR or MMR status.
- No requirement for any tumor cell surface receptor or ligand.
- 2:1 chance of randomization into Experimental Arm.
- Temporary IP catheter only in place for 1-2 weeks.
- NCCN Guidelines recommend platinum-based therapies for platinum-resistant patients.
- Olvi-Vec is an immune modulator believed to provide re-sensitization to platinum as demonstrated in Phase 2 VIRO-15 study (Holloway et al. JAMA Oncology, 2023; Holloway et al. Int J Gynecol Cancer, 2023).



Whom to Contact:

GOG Foundation/Partners

Katie Campbell
(kcampbell@gog.org)

Genelux Corporation

Jane LeBlanc, Clinical Site Liaison
(jane.leblanc@genelux.com)

To learn more, please visit:

www.genelux.com

www.clinicaltrials.gov/NCT05281471

